The immune checkpoint B7-H3 (CD276), a member of the B7 family with immunoregulatory properties, has been identified recently as a novel target for immunotherapy for refractory blood cancers and solid malignant tumors. The gene discussed is CD276; the disease is hematopoietic and lymphoid system neoplasm.